New posts

Reply to thread

Message

Most likely being Specced on the expected results in the upcoming Quarterly. PTX-200 (higher dose level) and PTX-100 results

They have about $17 million in the bank and still under the $100 mill market cap

You still own this one Rock?

Subsequent to the end of the quarter, the Phase 1b clinical study of PTX-200 and cytarabine in patients with acute myeloid leukemia (AML) successfully completed the second cohort at 35 mg/m2 PTX-200 under the modified study protocol, with no dose limiting toxicities observed. The safe completion of this cohort suggests that AML patients are able to better tolerate the combination of PTX-200 and cytarabine under the modified protocol. As planned, the study has now progressed to the next dose level of 45 mg/m2 PTX-200.

The Phase 1b basket study of PTX-100 in several solid and haematological cancers has recruited patients for the highest dose level of 2,000 mg/m2. As detailed in previous updates, a number of patients remained on the therapy longer than anticipated which has required additional manufacturing. Manufacturing is currently underway and is on schedule. Headline safety results are expected to be reported in the coming quarter

<blockquote data-quote="barney" data-source="post: 1123755" data-attributes="member: 4670">Most likely being Specced on the expected results in the upcoming Quarterly.&nbsp; PTX-200 (higher dose level) and PTX-100 resultsThey have about $17 million in the bank and still under the $100 mill market capYou still own this one Rock?Subsequent to the end of the quarter, the Phase 1b clinical study of PTX-200 and cytarabine in patients with acute myeloid leukemia (AML) successfully completed the second cohort at 35 mg/m2 PTX-200 under the modified study protocol, with no dose limiting toxicities observed. The safe completion of this cohort suggests that AML patients are able to better tolerate the combination of PTX-200 and cytarabine under the modified protocol. As planned, the study has now progressed to the next dose level of 45 mg/m2 PTX-200.The Phase 1b basket study of PTX-100 in several solid and haematological cancers has recruited patients for the highest dose level of 2,000 mg/m2. As detailed in previous updates, a number of patients remained on the therapy longer than anticipated which has required additional manufacturing. Manufacturing is currently underway and is on schedule. Headline safety results are expected to be reported in the coming quarter</blockquote>

[QUOTE="barney, post: 1123755, member: 4670"] Most likely being Specced on the expected results in the upcoming Quarterly. PTX-200 (higher dose level) and PTX-100 results They have about $17 million in the bank and still under the $100 mill market cap You still own this one Rock? Subsequent to the end of the quarter, the Phase 1b clinical study of PTX-200 and cytarabine in patients with acute myeloid leukemia (AML) successfully completed the second cohort at 35 mg/m2 PTX-200 under the modified study protocol, with no dose limiting toxicities observed. The safe completion of this cohort suggests that AML [B]patients are able to better tolerate the combination[/B] of PTX-200 and cytarabine under the modified protocol. As planned, the study has now progressed to the [B]next dose level of 45 mg/m2 PTX-200[/B]. The Phase 1b basket study of PTX-100 in several solid and haematological cancers has recruited patients for the highest dose level of 2,000 mg/m2. As detailed in previous updates, a number of patients remained on the therapy longer than anticipated which has required additional manufacturing. Manufacturing is currently underway and is on schedule. Headline safety [B]results are expected to be reported in the coming quarter[/B] [/QUOTE]

Verification